REZZAYO
Total Payments
$314,928
Transactions
22
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $314,928 | 22 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $295,741 | 14 | 93.9% |
| Consulting Fee | $19,188 | 8 | 6.1% |
Payments by Type
Research
$295,741
14 transactions
General
$19,188
8 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT) | Cidara Therapeutics, Inc. | $295,741 | 0 |
Top Doctors Receiving Payments for REZZAYO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $295,741 | 14 |
| , M.D | Infectious Disease | Bellaire, TX | $6,800 | 3 |
| , MD | Medical Oncology | Gainesville, FL | $6,300 | 2 |
| , MD | Medical Oncology | New York, NY | $3,263 | 1 |
| Peter Pappas | Infectious Disease | Birmingham, AL | $1,600 | 1 |
| , MD | Pulmonary Disease | Saint Louis, MO | $1,225 | 1 |
Ad
Manufacturing Companies
- Cidara Therapeutics, Inc. $314,928
Product Information
- Type Drug
- Total Payments $314,928
- Total Doctors 5
- Transactions 22
About REZZAYO
REZZAYO is a drug associated with $314,928 in payments to 5 healthcare providers, recorded across 22 transactions in the CMS Open Payments database. The primary manufacturer is Cidara Therapeutics, Inc..
Payment data is available from 2023 to 2023. In 2023, $314,928 was paid across 22 transactions to 5 doctors.
The most common payment nature for REZZAYO is "Unspecified" ($295,741, 93.9% of total).
REZZAYO is associated with 1 research study, including "Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT)" ($295,741).